drugset / Trial / NCT01972672
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
Phase 2
Completed
70 enrolled
Beijing Shenogen Biomedical Co., Ltd
307 Hospital of PLA · collabChinese Academy of Medical Sciences · collabNanJing PLA 81 Hospital · collabQingdao University · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to assess the time to progression (TTP) in patients with advanced HCC treated with Icaritin .
Timeline
- Start
- 2013-10
- Primary completion
- 2015-08
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icaritin | Small molecule | 600 mg | Oral |